Clinical trial

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Trastuzumab deruxtecan Normalized identity: trastuzumab deruxtecanView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pertuzumab Normalized identity: pertuzumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Tucatinib Normalized identity: tucatinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-12-28

PhasePHASE1 / PHASE2

Conditions

Metastatic Breast Cancerunresolved

Interventions

Trastuzumab deruxtecanDRUG · verified · RxNorm: trastuzumab deruxtecan

DurvalumabDRUG · verified · RxNorm: durvalumab

PaclitaxelDRUG · verified · RxNorm: paclitaxel

PertuzumabDRUG · verified · RxNorm: pertuzumab

TucatinibDRUG · verified · RxNorm: tucatinib

Sponsors & collaborators

AstraZenecalead sponsor

Daiichi Sankyo Company, Limitedcollaborator

Mapped research locations

MoscowRussia7 TaipeiTaiwan5 SeoulSouth Korea4 Saint PetersburgRussia3 New YorkNew York, United States2 MadridSpain2 IstanbulTurkey (Türkiye)2 São PauloBrazil2 Porto AlegreBrazil2 NashvilleTennessee, United States1 BarcelonaSpain1 ColumbusOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04538742 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.